2026 Medical Device Regulatory Updates: Why Compliance Now Depends on Connected Data

For years, many medical device companies managed regulatory requirements through disconnected systems, manual spreadsheets, department-specific processes, and periodic compliance reviews. That model is becoming harder to sustain. The shift is most visible in two major areas: the mandatory rollout of key EUDAMED modules in the European Union and FDA’s transition to the Quality Management System Regulation in the United States.

Collectively, these updates signal a clear change in regulatory expectations. Regulators are no longer only asking whether documentation exists. They are increasingly looking at whether product, quality, regulatory, supplier, risk, and post-market data maintain a consistent narrative.

What Changed in 2026?

EUDAMED is now mandatory for four core modules

As of May 28, 2026, the first four EUDAMED modules became subject to mandatory use requirements. The European Commission states that the first four mandatory modules are Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance. The transition was triggered by Commission Decision (EU) 2025/2371, which confirmed that these EUDAMED electronic systems had achieved functionality and met the relevant functional specifications. European Commission EUDAMED update and Commission Decision (EU) 2025/2371

Actor Registration, UDI/Device Registration, and Notified Bodies and Certificates directly affect manufacturers and other economic operators. The Market Surveillance module is primarily used by Competent Authorities and the European Commission, which is distinct from manufacturers’ post-market surveillance obligations under MDR and IVDR.

This marks a significant shift for companies placing medical devices on the EU market. Information that previously lived across separate national systems, internal spreadsheets, and disconnected regulatory files is now being centralized into a more transparent European database. If an economic-operator record does not align with device registration data, if certificate scope does not match the registered portfolio, or if UDI data is incomplete, those gaps are easier to detect.

FDA QMSR aligns U.S. quality requirements with ISO 13485

In the United States, FDA’s Quality Management System Regulation became effective on February 2, 2026. FDA states that QMSR amends device CGMP requirements under 21 CFR Part 820 and incorporates ISO 13485:2016 by reference. FDA QMSR overview

This does not mean FDA oversight has become less rigorous. In many ways, it has become more connected. FDA’s QMSR FAQ states that the agency stopped using the Quality System Inspection Technique on February 2, 2026 and began using the updated Inspection of Medical Device Manufacturers Compliance Program 7382.850. FDA QMSR FAQ

In practical terms, companies need to prove that their quality system is not just documented, but logically connected. Inspectors may look at how complaint signals connect to risk management, how supplier issues connect to corrective and preventive actions, and how management oversight supports product safety and quality.

UDI requirements continue to mature

The FDA’s Unique Device Identification System requires most device labels and packages to include a unique device identifier, and in some cases the identifier must appear directly on the device. FDA’s Global Unique Device Identification Database serves as the reference catalog for every device with a UDI. FDA UDI System and FDA GUDID

For EU market access, UDI is also central to device registration under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation. Product identifiers, Basic UDI-DIs, UDI-DIs, product families, packaging levels, nomenclature codes, certificates, and market-status data must be accurate, complete, and aligned.

Why This Matters: Compliance Is Becoming a Data Quality Problem

The most important lesson from the 2026 updates is that compliance risk increasingly starts with data quality. Companies preparing for EUDAMED often discover that required UDI and product data is incomplete, inconsistent, or distributed across systems without a reliable source of truth.

Common issues include missing Basic UDI-DIs, inconsistent product names, incorrect device classifications, outdated certificate references, missing nomenclature codes, and mismatches between regulatory records and ERP data. These are not just administrative problems. They can delay submissions, create registration errors, trigger batch rejections, and surface as inconsistencies during regulatory review.

The same logic applies to QMSR readiness. Complaint records, risk files, CAPAs, supplier records, and management-review evidence may each exist individually, but they often fail to connect into one traceable narrative. Without that connectivity, demonstrating system effectiveness during an inspection becomes much harder.

The Business Impact of Poor Regulatory Data

Organizational silos are also becoming compliance gaps. EUDAMED touches regulatory affairs, IT, supply chain, master data, notified body management, labeling, and quality. QMSR connects quality, engineering, supplier controls, complaint handling, risk management, and leadership oversight. When these functions operate separately, small data inconsistencies can become regulatory problems.

From Checkbox Compliance to Connected Compliance

The 2026 updates should not be viewed as isolated regulatory tasks. They are part of a broader shift toward connected compliance. A connected compliance model has five key characteristics.

Where Automation Can Help

Automation is becoming essential for medical device regulatory operations, especially for companies with large product portfolios or complex market footprints. The goal is not to remove human oversight. The goal is to reduce manual burden, improve data consistency, and give teams better visibility before issues become findings.

For EUDAMED, automation can support:

• Bulk XML submissions
• Machine-to-Machine integration
• UDI data validation
• Product registration workflows
• Certificate and device data reconciliation
• Missing field detection
• Submission readiness checks
• Legacy device data cleanup

For QMSR readiness, automation can support:

• Complaint-to-risk traceability checks
• CAPA workflow consistency
• Supplier data review
• Audit-trail documentation
• Management-review evidence preparation
• Quality-record completeness checks
• Cross-system reporting

Why Companies Should Act Now

The biggest mistake medical device companies can make is treating these regulatory changes as last-minute submission projects. By the time a submission is due, the underlying data problems have already accumulated. Missing fields, inconsistent identifiers, outdated certificates, disconnected risk files, and unclear ownership cannot be fixed sustainably through manual cleanup alone.

A better approach is to start with a structured readiness assessment. Companies should ask:

• Are our UDI and device records complete and consistent?
• Do our certificates align with our registered device portfolio?
• Can we support EUDAMED submissions at scale?
• Do we have a clear source of truth for product master data?
• Can we trace complaint signals back to risk management and CAPA?
• Are our supplier, quality, and regulatory records connected?
• Which legacy SKUs may no longer justify their compliance cost?
• Is our organization ready for connected, data-driven regulatory oversight?

How Supply Chain Wizard Helps

Supply Chain Wizard helps medical device companies turn regulatory complexity into a structured digital transformation opportunity. Our work focuses on the systems, data, workflows, and governance needed to support global compliance at scale.

EUDAMED readiness and submission automation

SCW helps companies assess data readiness, identify gaps, validate required fields, and support scalable submission approaches, including bulk XML upload preparation and Machine-to-Machine integration strategies.

Master data and system integration

SCW helps companies move away from fragmented spreadsheets and disconnected systems by designing stronger master-data models, integration workflows, and single-source-of-truth structures across regulatory, quality, supply chain, and product systems.

Gap assessments and audit readiness

SCW assesses whether product records, UDI data, certificate information, risk files, complaints, CAPAs, and supplier records align across systems before inconsistencies become findings.

Partner and ecosystem alignment

Compliance does not stop inside the company. Suppliers, contract manufacturers, distributors, notified bodies, and other partners all contribute to the quality and reliability of regulatory data. SCW helps align the ecosystem so data exchange is consistent, controlled, and scalable.

Digital transformation beyond compliance

The real opportunity is not only to meet the latest mandate. It is to build a more resilient operating model. When regulatory, quality, and supply chain data are connected, companies gain better visibility, faster decision-making, and stronger control over their device portfolio.

Turning Regulatory Pressure into Competitive Advantage

The 2026 regulatory updates represent a turning point, not just a compliance milestone. They signal that regulators expect stronger data, stronger systems, and stronger lifecycle control.

Companies relying on manual workarounds face increasing inspection risk and operational burden. Companies investing in connected compliance gain a distinct edge by maintaining market access, improving decision-making, and optimizing portfolios with more reliable data.

The future of medical device compliance is not mere documentation. It is connected, validated, and traceable data.